

Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial

Submission date

02/01/2006

Recruitment status

No longer recruiting

Registration date

13/01/2006

Overall study status

Completed

Last Edited

18/02/2008

Condition category

Nutritional, Metabolic, Endocrine

☐ Prospectively registered

☐ Protocol

☐ Statistical analysis plan

☐ Results

☐ Individual participant data

☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Robert Bem

Contact details

Videnska 1958/9

Prague 4

Czech Republic

14021

Additional identifiers

Protocol serial number

MZO00023001

Study information

Scientific Title**Study objectives**

Intranasal calcitonin can be effective in the treatment of acute Charcot foot.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the local ethics committee, and all participants gave written informed consent.

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Diabetic Foot

Interventions

Intranasal Calcitonin 200 IU + Calcium 1000 mg per day or Calcium 1000 mg per day in monotherapy; two years follow-up period.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Calcitonin, calcium

Primary outcome(s)

1. Effect on bone remodeling markers
2. Markers of disease activity - skin temperature

Key secondary outcome(s)

1. Prevention of deformities
2. Shortening of the treatment
3. Recurrence of Charcot foot

Completion date

01/01/2007

Eligibility**Key inclusion criteria**

1. Acute Charcot foot
2. Type 1 or Type 2 Diabetes

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Foot ulcer
2. Acute osteomyelitis

Date of first enrolment

01/08/2003

Date of final enrolment

01/01/2007

Locations**Countries of recruitment**

Czech Republic

Study participating centre

Videnska 1958/9

Prague 4

Czech Republic

14021

Sponsor information**Organisation**

Institute for Clinical and Experimental Medicine (Czech Republic)

ROR

<https://ror.org/036zr1b90>

Funder(s)

Funder type

Research organisation

Funder Name

Institute for Clinical and Experimental Medicine MZO00023001 (Czech Republic)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration